Grant: Proof of Principle Program - Phase I

The objective of this project is to further the development of NIMoEsh, a peptide that is a potential clinical candidate for the treatment of ischemic stroke. The overall question that will be addressed in this project is whether the NIMoEsh peptide is a viable therapeutic when given by IV delivery. There are currently no agents that provide effective neuroprotection for the damage associated with stroke. Every year, approximately 800,000 patients in the US suffer a stroke, and about 144,000 of those people die from stroke. In addition, a significant number of patients are left permanently disabled and represent a considerable burden to the healthcare system. The proposed research project has a very strong potential for commercial success. The project benefits from excellent proof-of-concept data, including in vivo data demonstrating efficacy in improving physiological AND behavioral outcomes even when the peptide is administered 6-h post stroke.